Digene finally able to take DNA HPV (human papillomavirus) test to $400 million market
This article was originally published in Clinica
Executive Summary
The US FDA has approved Digene's DNA test for the human papillomavirus as a primary screening tool for the detection of cervical cancer in women aged 30 and over. It is intended to be used in combination with the 50-year-old Pap smear, the FDA said.